2013ÔÇÖs best performing IPOs (so far)

3. Epizyme Inc (EPZM)

Gain: 175%
Offer price: $15
Recent close: $41
Offer Date: 30-May-2013

Epizyme, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, planning, and commercialization of various personalized therapeutics for the treatment of patients with genetically defined cancers, mixed lineage rearranged leukemia (MLL-r); and non-Hodgkin lymphoma. The company has strategic collaboration and license agreements with Celgene Corporation and Celgene International Sàrl, as well as Glaxo Group Limited to discover, develop, and commercialize small molecule HMT inhibitors; and Eisai Co., Ltd. (Eisai) to license its EZH2 program. It also has a companion diagnostic collaboration with Abbott Molecular Inc, Roche Molecular Systems, Inc as well as with Eisai. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.